|
BSG House, London, UK
Podium Presentation by Dr. Michael G. Palfreyman Head, Translational R&D, ChemDiv / Executive Program Director, Senior Scientific Advisor, EnVivo Pharmaceuticals
March 16 at 2:10PM
Use of biomarkers for demonstrating CNS effects of drugs early in clinical development
• Using animal PK/PD data to set dose range finding in Phase 1
• Use of QEEG to demonstrate CNS activity
• Computer measures of cognition
• Evoked potentials to demonstrate clinical potential
For more information about this event visit http://www.bioportfolio.com/cgi-bin/acatalog/CNS-Clinical-Trials.html |
